(BTSG) BrightSpring Health - Ratings and Ratios
Pharmacy,Rehabilitation,Nursing,Infused,Behavioral
BTSG EPS (Earnings per Share)
BTSG Revenue
Description: BTSG BrightSpring Health August 03, 2025
BrightSpring Health Services, Inc. is a healthcare services platform operating in the United States, providing home and community-based services through its two segments: Pharmacy Solutions and Provider Services. The company delivers pharmacy and provider services, including clinical and supportive care, to Medicare, Medicaid, and insured populations.
To further analyze the companys performance, we can examine key performance indicators (KPIs) such as revenue growth, operating margins, and patient satisfaction. BrightSpring Health Services, Inc. has likely experienced growth in revenue due to the increasing demand for home and community-based healthcare services. The companys operating margins may be influenced by its ability to manage costs and optimize its services. Additionally, patient satisfaction is a crucial KPI in the healthcare industry, and BrightSpring Health Services, Inc. may focus on delivering high-quality care to achieve high patient satisfaction ratings.
From a financial perspective, BrightSpring Health Services, Inc.s market capitalization is approximately $3.53 billion, indicating a significant presence in the healthcare services industry. The companys price-to-earnings (P/E) ratio is 74.44, which may suggest that the stock is overvalued. However, the forward P/E ratio is 25.91, indicating potential for future earnings growth. The return on equity (RoE) is 3.50, which may be considered relatively low, suggesting that the company may not be generating sufficient returns on shareholder equity.
To evaluate the stocks potential, we can also consider its support and resistance levels. The stock has support levels at $18.7, $18.0, $17.0, and $14.9, indicating potential buying opportunities. Resistance levels are at $21.4 and $24.1, suggesting potential selling pressure. By analyzing these levels, investors can make informed decisions about buying or selling the stock.
BTSG Stock Overview
| Market Cap in USD | 5,914m |
| Sub-Industry | Health Care Services |
| IPO / Inception | 2024-01-26 |
BTSG Stock Ratings
| Growth Rating | 90.4% |
| Fundamental | 61.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 55.9% |
| Analyst Rating | 4.67 of 5 |
BTSG Dividends
Currently no dividends paidBTSG Growth Ratios
| Growth Correlation 3m | 96.9% |
| Growth Correlation 12m | 72.4% |
| Growth Correlation 5y | 93.7% |
| CAGR 5y | 85.01% |
| CAGR/Max DD 3y (Calmar Ratio) | 2.39 |
| CAGR/Mean DD 3y (Pain Ratio) | 9.82 |
| Sharpe Ratio 12m | 0.98 |
| Alpha | 65.71 |
| Beta | |
| Volatility | 46.00% |
| Current Volume | 3546.3k |
| Average Volume 20d | 3546.3k |
| Stop Loss | 31.1 (-4.8%) |
| Signal | 0.50 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (129.6m TTM) > 0 and > 6% of Revenue (6% = 744.8m TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA 5.08pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 9.91% (prev 4.33%; Δ 5.58pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 349.2m > Net Income 129.6m (YES >=105%, WARN >=100%) |
| Net Debt (93.6m) to EBITDA (445.8m) ratio: 0.21 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.79 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (218.5m) change vs 12m ago 10.09% (target <= -2.0% for YES) |
| Gross Margin 12.30% (prev 12.08%; Δ 0.22pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 209.8% (prev 178.0%; Δ 31.78pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.53 (EBITDA TTM 445.8m / Interest Expense TTM 173.6m) >= 6 (WARN >= 3) |
Altman Z'' 1.55
| (A) 0.20 = (Total Current Assets 2.78b - Total Current Liabilities 1.55b) / Total Assets 6.05b |
| (B) -0.02 = Retained Earnings (Balance) -108.6m / Total Assets 6.05b |
| (C) 0.04 = EBIT TTM 266.2m / Avg Total Assets 5.92b |
| (D) -0.03 = Book Value of Equity -113.1m / Total Liabilities 4.23b |
| Total Rating: 1.55 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 61.21
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 4.60% = 2.30 |
| 3. FCF Margin 2.22% = 0.56 |
| 4. Debt/Equity 0.13 = 2.49 |
| 5. Debt/Ebitda 0.21 = 2.47 |
| 6. ROIC - WACC (= -6.19)% = -7.73 |
| 7. RoE 7.52% = 0.63 |
| 8. Rev. Trend 97.40% = 7.30 |
| 9. EPS Trend 63.96% = 3.20 |
What is the price of BTSG shares?
Over the past week, the price has changed by -4.02%, over one month by +13.20%, over three months by +64.63% and over the past year by +85.37%.
Is BrightSpring Health a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BTSG is around 38.72 USD . This means that BTSG is currently undervalued and has a potential upside of +18.48% (Margin of Safety).
Is BTSG a buy, sell or hold?
- Strong Buy: 9
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BTSG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 37.5 | 14.6% |
| Analysts Target Price | 37.5 | 14.6% |
| ValueRay Target Price | 44.1 | 35% |
BTSG Fundamental Data Overview November 01, 2025
P/E Trailing = 60.7222
P/E Forward = 25.641
P/S = 0.4446
P/B = 2.9222
Beta = None
Revenue TTM = 12.41b USD
EBIT TTM = 266.2m USD
EBITDA TTM = 445.8m USD
Long Term Debt = 2.56b USD (from longTermDebt, last fiscal year)
Short Term Debt = 94.8m USD (from shortTermDebt, last quarter)
Debt = 234.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 93.6m USD (from netDebt column, last quarter)
Enterprise Value = 6.01b USD (5.91b + Debt 234.0m - CCE 140.3m)
Interest Coverage Ratio = 1.53 (Ebit TTM 266.2m / Interest Expense TTM 173.6m)
FCF Yield = 4.60% (FCF TTM 276.1m / Enterprise Value 6.01b)
FCF Margin = 2.22% (FCF TTM 276.1m / Revenue TTM 12.41b)
Net Margin = 1.04% (Net Income TTM 129.6m / Revenue TTM 12.41b)
Gross Margin = 12.30% ((Revenue TTM 12.41b - Cost of Revenue TTM 10.89b) / Revenue TTM)
Gross Margin QoQ = 11.76% (prev 11.91%)
Tobins Q-Ratio = 0.99 (Enterprise Value 6.01b / Total Assets 6.05b)
Interest Expense / Debt = 16.34% (Interest Expense 38.2m / Debt 234.0m)
Taxrate = 24.43% (12.1m / 49.6m)
NOPAT = 201.2m (EBIT 266.2m * (1 - 24.43%))
Current Ratio = 1.79 (Total Current Assets 2.78b / Total Current Liabilities 1.55b)
Debt / Equity = 0.13 (Debt 234.0m / totalStockholderEquity, last quarter 1.82b)
Debt / EBITDA = 0.21 (Net Debt 93.6m / EBITDA 445.8m)
Debt / FCF = 0.34 (Net Debt 93.6m / FCF TTM 276.1m)
Total Stockholder Equity = 1.72b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.14% (Net Income 129.6m / Total Assets 6.05b)
RoE = 7.52% (Net Income TTM 129.6m / Total Stockholder Equity 1.72b)
RoCE = 6.21% (EBIT 266.2m / Capital Employed (Equity 1.72b + L.T.Debt 2.56b))
RoIC = 4.73% (NOPAT 201.2m / Invested Capital 4.25b)
WACC = 10.92% (E(5.91b)/V(6.15b) * Re(10.86%) + D(234.0m)/V(6.15b) * Rd(16.34%) * (1-Tc(0.24)))
Discount Rate = 10.86% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 12.98%
[DCF Debug] Terminal Value 58.91% ; FCFE base≈276.1m ; Y1≈181.3m ; Y5≈82.9m
Fair Price DCF = 6.11 (DCF Value 1.10b / Shares Outstanding 180.4m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 63.96 | EPS CAGR: 54.57% | SUE: 1.10 | # QB: 1
Revenue Correlation: 97.40 | Revenue CAGR: 21.07% | SUE: 2.04 | # QB: 3
Additional Sources for BTSG Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle